GW Pharma's cannabis drug fails in cancer pain study, shares fall

GW Pharma's cannabis drug fails in cancer pain study, shares fall

LONDON (Reuters) – An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday. GW, which is developing the drug …

8
Like
Save

Comments

Write a comment

*